A higher risk of sudden cardiac death is predicted by the presence of the following risk factors: Family history of sudden cardiac death due to hypertrophic cardiomyopathy, cardiac arrest, or sustained ventricular arrhythmias Personal history of unexplained syncope, cardiac arrest, or sustained ventricular arrhythmias Multiple repetitive non-sustained ventricular tachycardia (on ambulatory ECG) Massive left-ventricular hypertrophy (thickness ≥ 30 mm), LV dysfunction (EF < 50%), LV apical aneurysm Extensive and diffuse late gadolinium enhancement on MRI Treatment of Hypertrophic Cardiomyopathy Beta-blockers Rate-limiting and negative inotropic calcium channel blockers Mavacamten Avoidance of nitrates, diuretics, and angiotensin-converting enzyme (ACE) inhibitors Possibly antiarrhythmics (eg, disopyramide, amiodarone) Possibly implantable cardioverter-defibrillator and sometimes surgery or ablative procedures Treatment of hypertrophic cardiomyopathy is based on the phenotype.